Serum cytokine profiles and Mac-2 binding protein glycosylation isomer (M2BPGi) level in patients with autoimmune hepatitis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE
    • Publication Information:
      Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
    • Subject Terms:
      Antigens, Neoplasm/*analysis ; Cytokines/*analysis ; Hepatitis, Autoimmune/*blood ; Membrane Glycoproteins/*analysis; Aged ; Antigens, Neoplasm/blood ; Chemokines/analysis ; Chemokines/blood ; Cytokines/blood ; Female ; Hepatitis, Autoimmune/complications ; Humans ; Japan ; Male ; Membrane Glycoproteins/blood ; Middle Aged ; Research Design
    • Abstract:
      Autoimmune hepatitis (AIH) is an autoimmune liver disease that is characterized by a progressive destruction of the liver parenchyma and the development of liver fibrosis. We aimed to examine the relationship between circulating cytokines/chemokines and the Mac-2 binding protein glycosylation isomer (M2BPGi) levels in Japanese patients with autoimmune hepatitis (AIH).We investigated the relationship between circulating cytokines/chemokines and M2BPGi levels in Japanese patients with AIH. Seventy-seven patients with well-documented AIH were enrolled in the National Hospital Organization (NHO)-AIH-liver-network database. We measured the serum levels of 20 cytokines in 31 selected AIH patients before and after steroid treatment using multisuspension cytokine array.Eleven cytokines and soluble adhesion molecules were increased in untreated AIH patients compared with treated AIH patients. Among these cytokines and soluble adhesion molecules, soluble intercellular adhesion molecule-1 (sICAM-1) and interferon-γ-inducible protein 10 (IP-10) were most downregulated by steroid therapy in AIH patients. We measured serum sICAM-1 and IP-10 by ELISA and found the levels were significantly higher in AIH patients (n = 77) compared with chronic viral hepatitis C patients (n = 32). Furthermore, there was a positive correlation between sICAM-1 or IP-10 and alanine aminotransferase, total bilirubin, and circulating M2BPGi levels. M2BPGi levels were increased in AIH patients with high stages of liver fibrosis. Additionally, M2BPGi levels were correlated with the histological grade of inflammation in AIH. Circulating M2BPGi levels were significantly reduced by steroid treatment in AIH patients.sICAM-1 and IP-10 are useful markers to assess immune-mediated hepatitis activity in AIH and they correlate with circulating M2BPGi. Serum M2BPGi levels increased in untreated AIH patients with active hepatitis and were decreased by steroid therapy. M2BPGi reflects autoimmune-mediated hepatic inflammation as well as liver fibrosis.
    • References:
      J Gastroenterol Hepatol. 2017 Jul;32(7):1387-1393. (PMID: 28008658)
      J Gastroenterol. 2017 Dec;52(12):1252-1257. (PMID: 28477171)
      Hepatol Res. 2016 Jun;46(7):613-21. (PMID: 26406984)
      J Gastroenterol Hepatol. 2017 Dec;32(12):1922-1930. (PMID: 28406534)
      Hepatology. 2014 Nov;60(5):1563-70. (PMID: 25042054)
      J Gastroenterol. 2015 Jan;50(1):76-84. (PMID: 24603981)
      J Gastroenterol. 2015 Jul;50(7):776-84. (PMID: 25326152)
      Cell. 1990 Apr 20;61(2):243-54. (PMID: 1970514)
      Arthritis Rheum. 2010 Feb;62(2):383-91. (PMID: 20112361)
      J Hepatol. 1999 Nov;31(5):929-38. (PMID: 10580593)
      J Gastroenterol. 2011 Jan;46 Suppl 1:56-62. (PMID: 21042923)
      Hepatology. 1994 Jun;19(6):1513-20. (PMID: 8188183)
      Intern Med. 2015;54(11):1323-8. (PMID: 26027981)
      Hepatol Res. 2011 Apr;41(4):350-7. (PMID: 21426452)
      Dig Dis Sci. 1997 Nov;42(11):2277-84. (PMID: 9398806)
      Am J Gastroenterol. 2015 Jun;110(6):857-64. (PMID: 25916223)
      J Hepatol. 2005 Dec;43(6):951-7. (PMID: 16143423)
      J Autoimmun. 2010 Feb;34(1):7-14. (PMID: 19766456)
      N Engl J Med. 2006 Jan 5;354(1):54-66. (PMID: 16394302)
      Medicine (Baltimore). 2016 Apr;95(16):e3449. (PMID: 27100444)
      J Hepatol. 2001 Nov;35(5):582-9. (PMID: 11690703)
      J Immunol. 1995 Oct 1;155(7):3578-84. (PMID: 7561056)
      Liver Int. 2012 May;32(5):837-44. (PMID: 22221966)
      Best Pract Res Clin Gastroenterol. 2011 Dec;25(6):653-64. (PMID: 22117632)
      Annu Rev Immunol. 2009;27:147-63. (PMID: 19302037)
    • Accession Number:
      0 (Antigens, Neoplasm)
      0 (Chemokines)
      0 (Cytokines)
      0 (Membrane Glycoproteins)
      0 (TAA90K protein, human)
    • Publication Date:
      Date Created: 20181219 Date Completed: 20190107 Latest Revision: 20221005
    • Publication Date:
      20240829
    • Accession Number:
      PMC6320116
    • Accession Number:
      10.1097/MD.0000000000013450
    • Accession Number:
      30557999